<div>Researchers in China have conducted a phase 1/2 trial demonstrating the safety, tolerability, and immunogenicity of a candidate vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) &ndash; the agent responsible for the current coronavirus disease 2019 (COVID-19) pandemic.</div>